BioWorld

Aug. 30, 2004

View Archived Issues

No Vote At FDA Advisory Panel For Eyetech, Pfizer's Macugen

ROCKVILLE, Md. - An FDA advisory panel Friday leaned toward favoring Macugen, a proposed treatment for age-related macular degeneration expected to have an impact on the aging Baby Boomer population. (BioWorld Today) Read More

Manufacturing Misstep Delays Chiron Flu Vaccine Shipments

Read More

Critics: SEC Rules Blocking Naked Shorts' Not Adequate

Read More

Other News To Note

Read More

U.S. Patent Disclosures

Read More